Excerpted from CCHR’s submission to the FDA opposing its 2015 proposal to reclassify the ECT device as a Class II low risk device. CCHR’s submission was submitted in March 2016. In May 2006, Harold Robertson and Robin Pryor writing in BJPsych, “Memory and cognitive effects of ECT: informing and assessing patients,” determined: “Data do not … Read more
Excerpted from CCHR’s submission to the FDA opposing its 2015 proposal to reclassify the ECT device as a Class II low risk device. CCHR’s submission was submitted in March 2016. It is clear that the Food and Drug Administration (FDA) and American Psychiatric Association (APA) members know that the ECT device manufacturers are not going … Read more
Excerpted from CCHR’s submission to the FDA opposing its 2015 proposal to reclassify the ECT device as a Class II low risk device. CCHR’s submission was submitted in March 2016. The U.S. Food and Drug Administration (FDA) undermines the scores of studies and patient testimonies that indicate ECT causes brain damage. Dr. Lawrence Park, the … Read more
Excerpted from CCHR’s submission to the FDA opposing its 2015 proposal to reclassify the ECT device as a Class II low risk device. CCHR’s submission was submitted in March 2016. In 2013, Kathleen Lynch, Minister of State for Disability, Equality, Mental Health and Older People in Ireland stated that Ireland’s mental health law “will be … Read more